BOLT Stock Overview
An ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
BioLight Life Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪6.99 |
| 52 Week High | ₪7.02 |
| 52 Week Low | ₪3.34 |
| Beta | 0.58 |
| 1 Month Change | 18.78% |
| 3 Month Change | 52.08% |
| 1 Year Change | 45.16% |
| 3 Year Change | -37.16% |
| 5 Year Change | -22.62% |
| Change since IPO | -98.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOLT | IL Life Sciences | IL Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 0.05% |
| 1Y | 45.2% | 30.0% | 33.0% |
Return vs Industry: BOLT exceeded the IL Life Sciences industry which returned 30% over the past year.
Return vs Market: BOLT exceeded the IL Market which returned 33% over the past year.
Price Volatility
| BOLT volatility | |
|---|---|
| BOLT Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in IL Market | 9.0% |
| 10% least volatile stocks in IL Market | 3.0% |
Stable Share Price: BOLT's share price has been volatile over the past 3 months compared to the IL market.
Volatility Over Time: BOLT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Yaacov Michlin | bio-light.co.il |
BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company’s ophthalmic product offering and pipeline of product candidates include DiagnosTear’s TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival implant; OphRx that develops drugs for treating eye diseases; and Peripherex, which develops solutions for at-home and in-office diagnosis and monitoring of peripheral vision impairment used by eye care and other providers to diagnose and monitor glaucoma and other diseases. Its pipeline also include AEYE that develops artificial intelligence solutions for a variety of retinal diseases; Tarsier, which develops TRS 01 based on its technological platform for the treatment of Uveitis in patients suffering from high IPO; Belkin Vision that develops clinic fast and automatic laser device to enable glaucoma patients to receive short & effective treatments as treatment to lower IOP; and Sanoculis, which develops an innovative surgical procedure for the treatment of the Glaucoma.
BioLight Life Sciences Ltd. Fundamentals Summary
| BOLT fundamental statistics | |
|---|---|
| Market cap | ₪32.58m |
| Earnings (TTM) | -₪6.16m |
| Revenue (TTM) | ₪198.00k |
164.5x
P/S Ratio-5.3x
P/E RatioIs BOLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOLT income statement (TTM) | |
|---|---|
| Revenue | ₪198.00k |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪198.00k |
| Other Expenses | ₪6.36m |
| Earnings | -₪6.16m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.32 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,109.60% |
| Debt/Equity Ratio | 0% |
How did BOLT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 09:21 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioLight Life Sciences Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pooya Hemami | Edison Investment Research |
| Brian Murphy | Merriman Capital, Inc |
| Brian Marckx | Zacks Investment Research Inc. |